"Good-paying" manufacturing and scientific jobs should be available as soon as GlaxoSmithKline ($GSK) upgrades a production facility in Hamilton, MT. A state development grant of $240,000 will help GSK buy equipment for a manufacturing plant.
The plant produces an adjuvant used in Cervarix, the company's cervical cancer vaccine that competes with Merck's ($MRK) Gardasil. Cervarix was approved for use in the U.S. in 2009.
Cervarix launched with a slower-than-expected start. But as it began to gain worldwide traction last year, the company began adding employees, according to the Missoulian. At that point, the goal was 30, with 10 being temporary jobs. With the grant, the temp jobs may become permanent, the paper says.
- see the story